BARDA and Sonica Health expand partnership to develop wearable patch as an early monitoring platform for COVID-19 infection
BARDA and Sonica Health are expanding their partnership to include early identification of COVID-19 symptoms and other respiratory infections in high-risk clinical populations via wearable sensors.
People infected with SARS-CoV-2 and similar respiratory viruses typically only seek diagnostic tests after exhibiting symptoms. Sonica Health aims to disrupt this healthcare paradigm by detecting infection, especially in high-risk individuals, before the onset of noticeable symptoms, thereby reducing infection transmission.
In conjunction with Northwestern University and Shirley Ryan AbilityLab researchers, the team is creating and implementing a set of symptom-driven algorithms specifically tailored to catch early signs and symptoms associated with COVID-19 and to monitor patients throughout illness. Custom signal processing and machine-learning can reveal subtle, yet critical insight into health status using the continuous streams of data collected and wirelessly transmitted to a data hub. In addition, Sonica Health is working with Sibel Health to offer additional continuous pulse oximetry in one integrated digital health system.
Sonica Health is utilizing a bio-integrated, wearable patch called ADAM. The flexible wireless patch is a thin device about the size of a band-aid and sits at the base of the throat. The device monitors cough intensity and patterns; chest wall movements which can indicate labored or irregular breathing; other respiratory sounds; heart rate; physical activity; and temperature. Sonica Health will now expand this platform to include the option to deploy Sibel Health’s ANNETM One platform—this ICU-grade wearable sensor system offers the ability to add continuous pulse oximetry and electrocardiography.
In a team effort, Sonica will be conducting clinical studies among healthcare providers using these breakthrough, soft, and flexible sensors with the goal of developing infection detection algorithms for COVID-19. The overall goal is an FDA-cleared platform encompassing the sensors, algorithm, and software package as an early warning system for SARS-CoV-2 contraction, and prognosis, helping reduce the transmission of the infection through early detection.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About the Company:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
Sonica Health is a digital medicine company commercializing a breakthrough, body-integrated sensor technology. We exploit our ability to continuously capture acoustomechanic signatures and translate them into broad insights into human health. Sonica’s initial target focus is in health monitoring to support longevity and older adults. Both Sonica and Sibel Health are spinouts of Northwestern University’s Querrey Simpson Institute for Bioelectronics sharing manufacturing space.